Oppenheimer Initiates Coverage On Retension Pharmaceuticals with Outperform Rating, Announces Price Target of $50

Benzinga · 2d ago
Oppenheimer analyst Jay Olson initiates coverage on Retension Pharmaceuticals (NASDAQ:RTSN) with a Outperform rating and announces Price Target of $50.